Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection

NCT07335627 | Recruiting

• 1 other identifier: 9536
• Study Type: observational
• Target: 260
• Locations: 1 country
• Sites: 1

Brief Summary

Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained. The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections. The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.

Conditions

Streptococcus Infection

Keywords

Streptococcus Infection; Clindamycin; Antimicrobial Treatment; Osteoarticular infections; Amoxicillin

Outcome Measures

Primary Outcomes (1)

• Therapeutic success of the medical-surgical strategy

  Therapeutic success of the medical-surgical strategy defined as: patient showing no clinical signs of infection, no need for repeat surgery one year after the end of antibiotic treatment, and no repeat antibiotic treatment.

  One year after the end of antibiotic treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

\- Adult patient at the time of surgery for infection with a probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria

You may qualify if:

• Adult patient (aged 18 years or older) at the time of surgery for infection
• Probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria
• Patient operated on in one of the associated centers between 2013 and 2024

You may not qualify if:

• Patient who underwent joint resection or amputation
• Patient who was treated with suppressive antibiotic therapy (defined as antibiotic treatment lasting more than 6 months) which was decided upon prior to surgery

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Streptococcal Infections

Condition Hierarchy (Ancestors)

Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Central Study Contacts

Stéphane KLEIN, MD

CONTACT

33 3 68 76 52 32; stephane.klein@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2026
• First Posted: January 13, 2026
• Study Start: February 21, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 21, 2026
• Last Updated: January 13, 2026

Record last verified: 2026-01

Locations

FR (1)